

Referenties combigebruik bij anabole steroïdengebruik

1. Smit D, de Ronde W. Outpatient clinic for users of anabolic androgenic steroids: an overview. *The Netherlands Journal of Medicine*. 2018;167.
2. Begley E, McVeigh J, Hope V. Image and Performance Enhancing Drugs National Survey Results. 2017.
3. Ip EJ, Doroudgar S, Lau B, Barnett MJ. Anabolic steroid users' misuse of non-traditional prescription drugs. *Research in Social and Administrative Pharmacy*. 2018.
4. Sagoe D, McVeigh J, Bjørnebekk A, Essilfie M-S, Andreassen CS, Pallesen S. Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis. *Substance Abuse Treatment, Prevention, and Policy*. 2015;10(1):12.
5. Pope Jr HG, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. *Endocrine reviews*. 2013;35(3):341-75.
6. Schwingel PA, Zoppi CC, Cotrim HP. The influence of concomitant use of alcohol, tobacco, cocaine, and anabolic steroids on lipid profiles of Brazilian recreational bodybuilders. *Substance use & misuse*. 2014;49(9):1115-25.
7. Darke S, Torok M, Duflou J. Sudden or unnatural deaths involving anabolic-androgenic steroids. *Journal of forensic sciences*. 2014;59(4):1025-8.
8. Ljungdahl S, Ehrnborg C, Eriksson B, Lindqvist Bagge A, Mo-berg T. Patients who Seek Treatment for AAS Abuse in Sweden: Description of Characteristics. *Substance Pattern and Mortality Rate J Addict Med Ther*. 2019;3(11).
9. Kanayama G, Pope HG, Hudson JI. Associations of anabolic-androgenic steroid use with other behavioral disorders: an analysis using directed acyclic graphs. *Psychological medicine*. 2018;48(15):2601-8.
10. Mhillaj E, Morgese MG, Tucci P, Bove M, Schiavone S, Trabace L. Effects of anabolic-androgens on brain reward function. *Frontiers in Neuroscience*. 2015;9(295).
11. Kanayama G, Cohane GH, Weiss RD, Pope HG. Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? *The Journal of clinical psychiatry*. 2003;64(2):156-60.
12. Gårevik N, Rane A. Dual use of anabolic-androgenic steroids and narcotics in Sweden. *Drug and Alcohol Dependence*. 2010;109(1):144-6.
13. Schwingel PA, Cotrim HP, dos Santos Jr CR, Dos Santos AO, de Andrade ARCF, Carruego MVVB, et al. Recreational anabolic-androgenic steroid use associated with liver injuries among Brazilian young men. *Substance use & misuse*. 2015;50(11):1490-8.
14. Krzyzak M, Elangovan N. Rhabdomyolysis in a Patient Taking Both Oxandrolone for Bodybuilding and Methamphetamine. *Cureus*. 2017;9(11).
15. Andrews MA, Magee CD, Combest TM, Allard RJ, Douglas KM. Physical Effects of Anabolic-androgenic Steroids in Healthy Exercising Adults: A Systematic Review and Meta-analysis. *Current sports medicine reports*. 2018;17(7):232-41.
16. Fett WCR. Blood Biochemical Markers of Competitive Bodybuilding Athletes Users of Anabolic Androgenic Steroids and/or Growth Hormone (AAS/GH), Strength Athletes Drugs Free and Sedentary Persons. 2018.

17. Rasmussen JJ, Schou M, Madsen PL, Selmer C, Johansen ML, Ulriksen PS, et al. Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids. *American Heart Journal*. 2018;203:49-56.
18. Chin-Yee B, Lazo-Langner A, Butler-Foster T, Hsia C, Chin-Yee I. Blood donation and testosterone replacement therapy. *Transfusion*. 2017;57(3):578-81.
19. Gheshlaghi F, Piri-Ardakani M-R, Masoumi GR, Behjati M, Paydar P. Cardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes. *Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences*. 2015;20(2):165.
20. Emamian M, Hasanian SM, Tayefi M, Bijari M, Movahedian Far F, Shafiee M, et al. Association of hematocrit with blood pressure and hypertension. *Journal of clinical laboratory analysis*. 2017;31(6).
21. Baggish AL, Weiner RB, Kanayama G, Hudson JI, Lu MT, Hoffmann U, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. *Circulation*. 2017;135(21):1991-2002.
22. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J*. 2017;38(32):2459-72.
23. MacDougall J, Tuxen D, Sale D, Moroz J, Sutton J. Arterial blood pressure response to heavy resistance exercise. *Journal of applied Physiology*. 1985;58(3):785-90.
24. Gupta A, Singh O. Sympathomimetic Drugs. *Principles and Practice of Critical Care Toxicology*. 2019:84.
25. Piacentino D, D Kotzalidis G, del Casale A, Rosaria Aromatario M, Pomara C, Girardi P, et al. Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review. *Current neuropharmacology*. 2015;13(1):101-21.
26. Hildebrandt T, Langenbucher JW, Flores A, Harty S, Berlin HA. The influence of age of onset and acute anabolic steroid exposure on cognitive performance, impulsivity, and aggression in men. *Psychology of addictive behaviors*. 2014;28(4):1096.
27. Carré JM, Geniole SN, Ortiz TL, Bird BM, Videto A, Bonin PL. Exogenous Testosterone Rapidly Increases Aggressive Behavior in Dominant and Impulsive Men. *Biological Psychiatry*. 2017;82(4):249-56.
28. Grant JE, Chamberlain SR. Impulsive action and impulsive choice across substance and behavioral addictions: Cause or consequence? *Addictive Behaviors*. 2014;39(11):1632-9.
29. Pillinger T, D'Ambrosio E, McCutcheon R, Howes OD. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. *Molecular psychiatry*. 2019;24(6):776.
30. Duffy RM, Kelly BD. Steroids, psychosis and poly-substance abuse. *Irish Journal of Psychological Medicine*. 2015;32(2):227-30.
31. Bawor M, Bami H, Dennis BB, Plater C, Worster A, Varenbut M, et al. Testosterone suppression in opioid users: A systematic review and meta-analysis. *Drug and Alcohol Dependence*. 2015;149:1-9.
32. Emanuele MA, Emanuele N. Alcohol and the male reproductive system. *Alcohol Research and Health*. 2001;25(4):282-7.
33. Duca Y, Aversa A, Condorelli RA, Calogero AE, Vignera SL. Substance Abuse and Male Hypogonadism. *Journal of clinical medicine*. 2019;8(5):732.

34. Kurling S, Kankaanpää A, Seppälä T. Sub-chronic nandrolone treatment modifies neurochemical and behavioral effects of amphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in rats. *Behavioural Brain Research*. 2008;189(1):191-201.
35. Célérier E, Ahdepil T, Wikander H, Berrendero F, Nyberg F, Maldonado R. Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence. *Neuropharmacology*. 2006;50(7):788-806.